APA (7th ed.) Citation

Yagi, K., Imamura, T., Tada, H., Chujo, D., Liu, J., Shima, Y., . . . Tobe, K. Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction. Wiley.

Chicago Style (17th ed.) Citation

Yagi, Kunimasa, et al. Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction. Wiley.

MLA (9th ed.) Citation

Yagi, Kunimasa, et al. Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction. Wiley.